


Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study


Andrew N Menzies-Gow, Claire McBrien, Bindhu Unni, Celeste M Porsbjerg, Mona Al-Ahmad, Christopher S Ambrose, Karin Dahl Assing, Anna von Bülow, John Busby, Borja G Cosio, J Mark FitzGerald, Esther Garcia Gil, Susanne Hansen, Liam G Heaney, Mark Hew, David J Jackson, Maria Kallieri, Stelios Loukides, Njira L Lugogo, Andriana I Papaioannou, Désirée Larenas-Linnemann, Wendy C Moore, Luis A Perez-de-Llano, Linda M Rasmussen, Johannes M Schmid, Salman Siddiqui, Marianna Alacqua, Trung N Tran, Charlotte Suppli Ulrik, John W Upham, Eileen Wang, Lakmini Bulathsinhala, Victoria A Carter, Isha Chaudhry, Neva Eleangovan, Ruth B Murray, Chris A Price, David B Price







Demographic and clinical characteristics of severe asthma patients before initiation of the first biologic



Pre-biologic initiation, stoppers and switchers were more likely to have poorer


Continued Stopped Switched

CRS and/or NP refers to CRS with NP, eosinophilic CRS or CRS without nasal polyps.

BEC = Blood eosinophil count; CRS = Chronic rhinosinusitis; FeNO = Fractional exhaled nitric oxide; FEV1 = Forced expiratory volume in 1 second; FVC = Forced vital capacity; LTOCS = Long-term oral corticosteroids; NP = Nasal polyps Menzies-Gow AN, Price D et al. J Asthma Allergy 2022;15:63-78.




Over time, the proportional use of Anti-IgE therapy \downarrow while that of Anti-IL5/5R therapies \uparrow .





IgE = Immunoglobulin E; IL5/5R = Interleukin 5/5 receptor Menzies-Gow AN, Price D et al. *J Asthma Allergy* 2022;15:63-78.








ISAR = International Severe Asthma Registry; CHRONICLE = Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States Menzies-Gow AN, Price D et al. J Asthma Allergy 2022;15:63-78.

Time to biologic cessation in patients with severe asthma




6

ISAR


Patterns of biologic switches for patients with severe asthma

Of patients who stopped or switched their first biologic, the most common first switch was from omalizumab to (or, rarely, combined with) an anti–IL-5/5R.



Patterns are mutually exclusive; : or, < , >: sequence of switch; +: add-on use

Patterns of biologic switches by age, LTOCS use, age of asthma onset and presence of nasal polyps



Presence of nasal polyps



CRSwNP No NP

Age of asthma onset



ISAR


ISAR ⁹

The most commonly cited reasons for stopping or switching a biologic were insufficient clinical efficacy and adverse outcomes

Reason	Stopped	Switched
	(n=139)	(n=280)
Reason available n (%)	113	183
Insufficient Clinical Efficacy	72 (63.7%)	158 (86.3%)
Potential Adverse Outcomes	18 (15.9%)	14 (7.7%)
Biologic Access Restriction	8 (7.1%)	5 (2.7%)
Patient Preference	4 (3.5%)	3 (1.6%)
Other	12 (10.6%)	11 (6.0%)



Sensitivity analyses of prospective and non-US patients: Patterns of biologic use




10

ISAR

eCRF = Electronic case report form; US = United States Menzies-Gow AN, Price D et al. J Asthma Allergy 2022;15:63-78.

Sensitivity analyses of prospective and non-US patients: Patterns of first biologic switch





OPC

eCRF = Electronic case report form; IgE = Immunoglobulin E; IL4 = Interleukin 4; IL5/5R = Interleukin 5/5 receptor; US = United States Menzies-Gow AN, Price D et al. J Asthma Allergy 2022;15:63-78.

Conclusions



Iournal of Asthma and Allergy

ORIGINAL RESEARCH

Dovepress

benefit from switching.

Real World Biologic Use and Switch Pattorns in Severe Asthma: Data fro Asthma Registry and the

> Introduction: Inter treating severe asthr

> elucidate reasons un

Methods: This was into the International

included (Bulgaria,

stopping biologic trea

switching were record

Andrew N Menzies-Gow,¹ Claire McBrien,² Bindhu Unni,³ Celeste M Porsbjerg,⁴ Mona Al-Ahmad, patterns of biologic Christopher S Ambrose, 60° Karin Dahl Assing.7 Anna von Bülow,4 John Busby,⁸ Borja G Cosio, S^o J Mark FitzGerald,¹⁰ Esther Garcia Gil,¹¹ Susanne Hansen,¹² Liam G aHeaney, Mark Hew,^{13,14} David I Jackson,^{15,16} the CHRONICLE S Maria Kallieri,17 Stelios Loukides, 0017 Njira L Lugogo,¹⁸ Andriana I Papaioannou, ¹² Désirée Larenas-Linnemann, ¹⁹ Wendy C Mosre,²⁶ UK and USA) Biole Luis A Perez, de, Llano 21 Linda M Rasmussen,22 Johannes M Schmid,2 Salman Siddiqui,24 Marianna Alacqua,21 Trung N Tran,⁶ Charlotte Suppli Ulrik. 2¹⁶ John W Upham, ²⁷ Eleen Wang, ^{21,10} Lakmini Bulathsinhala, ^{2,10} Victoria A Carter, 3,20 Isha Chaudhry, 3,30 Neva Beangoyan, 3,30 Ruth B Murray, ^{3,30} Chris A Price, ^{3,36} David B Price, ^{3,36,31}

UK Severe Asthena Network and National Registry, Royal Bromoton & Harefield Hospitals, London, UK: "Kingston Hospital, London, UK: 'Observational and Prognatic Research Inscitute, Singapore, Singapore; "Respiratory Research Unit, Bispabiers University Hespital, Copenhager, Demark: ¹Al-Rashed Allergy Center, Ministry of Heakh, Microbiology Department, Faculty of Hedkine, Kuwak University, Kuwak, Kuwak, AstraZeneca, Galthersburg, MD, USA Department of Respiratory Medkine, Aaborg University Hospital, Aalborg, Denmark, "UK Severa Asthma Network and National Registry, Queen's University Belfait, Belfait, Northern Ireland. "Son Espases University Hospital IdSBs-Clients, Malarca, Spain, ¹¹The Centre for Lung Health, Vancouver Cosstal Health Research Institute, UBC, Vancouver, Canada; ¹¹AstraZeneca, Barcelona, Spain; ¹²Center for **Clinical Research and Prevention. Bispebjerg** Cinical National Inter Prevention, Supplerg and Frederiksberg Hospikal, Copenhagen, Dennarit: "Allergy, Asthrea & Cinical Introducing Service, Alfred Health, Helbourne, Australia: "Public Health and Preventive Madates, Marsah University, Malanume. ustralia: "UK Severe Asthma Network and

biologic in 2015 (88.2%) and benalizumab in 2019 (29.6%). Most patients (79%; 2791/3531) continued their first biologic; 10.2% (356/3531) stopped; 10.8% (384/3531) switched. The most frequent first switch was from omalizumab to an anti-IL-5/5R (49.6%; 187/377). The most common subsequent switch was from one anti-IL-5/5R to another (44.4%; 20/45). Insufficient efficacy and/or adverse effects were the most frequent reasons for stopping/switching. Patients who stopped/switched were more likely to have a higher baseline blood eosinophil count and Conclusion: The description of real-life patterns of continuing, stopping, or swite

tologies enhances our understanding of global biologic use. Prospective studies invol tractured switching criteria could ascertain optimal strategies to identify patients who mefit from switching

Results: A total of 3531 patients were included. Omalizumab was the most common initial

Introduction

With the advent of personalized medicine, biologic therapy is becoming n widely used for a number of diseases, including severe asthma.¹ However, t is a paucity of literature on both the frequency and patterns of biologic use in se asthma, as well as the characterization of pre-biologic patient factors associ with stopping or switching versus continuation of the initial biologic.

Omalizumab was the first available biologic therapy for severe asthma, targe immunoglobulin E (IgE) and therefore the allergic asthma phenotype. In reyears, four more monoclonal antibodies have been added to the biologic reperts For the eosinophilic phenotype, there are three available biologic age

Received: 9 July 2021 Accepted: 23 December 2021 Published: 13 January 2022

ournal of Asthma and Allergy 2022:15 63-78 modes at all fees wat a published and laborating from Reductives lasted. The full transmit fee forces are could be artign. Over all imageness the indexes forces determined with the second standard and the second standard standard in the second standard standard standard in the second standard stan 000

Our findings naturally trigger the question: Is the first biologic prescribed to

a patient usually the best one for that individual, or are we under-

Conclusion: The description of real-life patterns of continuing, stopping, or switching

biologics enhances our understanding of global biologic use. Prospective studies involving

structured switching criteria could ascertain optimal strategies to identify patients who may





- We would like to thank all patients and collaborators who contributed to this research study.
- This research study was funded and delivered by the Observational and Pragmatic Research Institute Pte Ltd (OPRI). The International Severe Asthma Registry (ISAR) is co-funded by Optimum Patient Care Global Limited and AstraZeneca.
- Registration of the ISAR database with the European Union Electronic Register of Post-Authorization studies was also undertaken (ENCEPP/DSPP/23720). ISAR has ethical approval from the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218). All data collection sites in the International Severe Asthma Registry (ISAR) have obtained regulatory agreement in compliance with specific data transfer laws, countryspecific legislation, and relevant ethical boards and organizations.